But this is why we do actual… [bio-]science. Why we run independently-monitored, generally double-blinded clinical trials — with peer reviews, before publishing.
Knowing the actual facts… matters. Even when it means we need to look in other directions.
Heres’ the latest, from CIDRAP:
…The antiviral drug tecovirimat (Tpoxx) is no better than placebo in achieving a shorter time to clinical resolution, reduced pain, or increased viral DNA clearance in adults infected with clade 2 mpox virus, per a phase 3 randomized controlled trial published yesterday in the New England Journal of Medicine.
An international roster of investigators in the Advancing Clinical Therapeutics Globally Study of Tecovirimat for Human Mpox Virus (STOMP/A5418) group randomly assigned 412 participants in a 2:1 ratio to receive either tecovirimat (275 patients) or a placebo (137) for 14 days from September 2022 to October 2024….
At 29 days, the estimated cumulative rate of clinical resolution was 83% in tecovirimat recipients and 84% in those given placebo, and 79% of tecovirimat recipients and 81% in the placebo group had clinical resolution of skin lesions. The competing-risks hazard ratio (crHR) for clinical resolution was 0.98. No significant differences were observed between the two groups in pain reduction in participants reporting severe pain (difference, 0.1 point) or in complete lesion healing (crHR, 0.97)….
Onward, resolutely just the same. [And yep — this is power alley stuff.]
नमस्ते
Powerline Lies... 